Veeva Systems Inc.

VEEV Healthcare Health Information Services

Veeva Systems Inc.’s revenue for fiscal 2026 (year ended January 2026) was $3.2 billion, up 16.3% from fiscal 2025.

Revenue
+17.6%
EPS
+36.6%
Free cash flow
−0.62%

Quarter to July 2026, against a year earlier

303.26 6.84 −2.21%
Market cap
$50.2B
P/E
49.8×
Fwd P/E
47.9×
Dividend yield
—
F-score
7/9
Altman Z
13.57
Beneish M
−2.63
Dividend safety
n/a

Veeva Systems Inc. 10-Q filed Nov 21, 2025

Fiscal Q3 2026 · Period ended Oct 31, 2025 · Filed · accepted 4:07 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 29, 2025: 3 added · 17 modified; 16 with only figures updated

  1. Modified · Revenues

    We generally enter into master subscription agreements with our customers and count each distinct master subscription agreement that has not been terminated or expired and that has orders for which we have recognized revenue in the quarter as a distinct customer for purposes of determining our total number of current customers as of the end of that quarter. We generally enter into a single master subscription agreement with each customer, although in some instances, affiliated legal entities within the same corporate family may enter into separate master subscription agreements. Conversely, affiliated legal entities that maintain distinct master subscription agreements may choose to consolidate their orders under a single master subscription agreement, and, in that circumstance, our customer count would decrease. Divisions, subsidiaries, and operating units of our customers often place distinct orders for our subscription services under the same master subscription agreement, and we do not count such distinct orders as new customers for purposes of determining our total customer count. For purposes of determining customers of Veeva Crossix that do not contract under a master subscription agreement, we count each entity that has a statement of work or services agreement and a recurring known payment obligation as a distinct customer if such entity is not otherwise a customer of ours. For Veeva Crossix, we do not count as distinct customers agencies contracting with us on behalf of brands within life sciences companies.